Prognostic analysis of PD-1/CTLA-4 bispecific antibody combined with chemotherapy first-line treatment for recurrent or metastatic cervical cancer: A multicenter real-world study.

作者
Jiwei Li,Tao Wu,Yuping Deng,Chao Xu,Yupeng Jiang,Wen Zou,Yeqian Feng,Lin Wu,Jingjing Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): e17520-e17520 被引量:1
标识
DOI:10.1200/jco.2024.42.16_suppl.e17520
摘要

e17520 Background: PD-1/CTLA-4 bispecific antibody, cadonilimab, has shown excellent efficacy in advanced cervical cancer patients who have previously received platinum containing chemotherapy. However, its effectiveness in first-line treatment remains unclear yet. This study aims to evaluate the efficacy, safety, and prognostic biomarker of cadonilimab combined with chemotherapy for the first line treatment of recurrent or metastatic cervical cancer. Methods: Information on patients with recurrent or metastatic cervical cancer who received chemotherapy combined with cadonilimab as first-line treatment at three cancer centers from July 2022 to September 2023 were collected. Patients have not received systemic chemotherapy previously and are not suitable for curative local treatment, received cadonilimab 10mg/kg Q3W for up to 17 cycles + chemotherapy for up to 6 cycles (paclitaxel 135-175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5), ± bevacizumab 10-15 mg/kg. Clinical outcomes were analyzed using the Kaplan–Meier method with log-rank test. RNA-seq was used to analyze differential expressed genes (DEGs) between PR+CR group and PD+SD group. Results: There are 52 patients enrolled, median age 56.5 years (39–87 years). The median follow-up time was 12 months (5–23 months). There were 29 cases of lung metastasis, 7 cases of liver metastasis, 11 cases of bone metastasis, 12 cases of pelvic metastasis, and 11 cases of lymph node metastasis. The median number of cycles of cadonilimab and chemotherapy were 8 and 5, respectively. The 1-year overall survival (OS) and progression-free survival (PFS) rates were 91% and 72.5%, respectively. The objective response rate (ORR) was 75%.The expression of PD-L1 and bevacizumab had no effect on prognosis. The most common treatment-related adverse events (TRAEs) were neutropenia (78.2%), anemia (82.7%), thrombocytopenia (51.9%), thyroid dysfunction (50%), nausea and vomiting (88.5%), fatigue (71.2%). Grade 3 or 4 adverse events (AE) were reported in 36.5% patients, mainly hematological toxicity. The most significant differential pathways between PR+CR group and PD+SD group were adhesion, Hippo signaling pathway, NOD like receptor signaling pathway, programmed cell death, and secretory granules. Conclusions: Cadonilimab combined with chemotherapy ± bevacizumab as first-line treatment for recurrent or metastatic cervical cancer was effective and well-tolerant.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高高发布了新的文献求助10
刚刚
Hello的应助被HopeStar采纳,获得20
刚刚
ding的应助被Victor陈采纳,获得10
1秒前
1秒前
123完成签到,获得积分10
1秒前
2秒前
Lifel发布了新的文献求助10
2秒前
Lucas的应助被科研通管家采纳,获得10
2秒前
爆米花的应助被科研通管家采纳,获得10
2秒前
科目三的应助被273129425采纳,获得10
2秒前
温岚完成签到,获得积分10
2秒前
黄小小发布了新的文献求助10
2秒前
星辰大海的应助被科研通管家采纳,获得10
3秒前
科目三的应助被科研通管家采纳,获得10
3秒前
绵羊小姐发布了新的文献求助10
3秒前
Akim的应助被科研通管家采纳,获得10
3秒前
彭于晏的应助被lanbing802采纳,获得10
3秒前
李健的应助被妖妖林采纳,获得10
3秒前
3秒前
初景发布了新的文献求助50
3秒前
汉堡包的应助被科研通管家采纳,获得10
3秒前
Hello的应助被科研通管家采纳,获得10
3秒前
在水一方的应助被独自受罪采纳,获得10
3秒前
wanci的应助被科研通管家采纳,获得10
3秒前
李爱国的应助被科研通管家采纳,获得10
3秒前
大树梨完成签到,获得积分10
4秒前
ngMXPV的应助被科研通管家采纳,获得10
4秒前
Jasper的应助被科研通管家采纳,获得10
4秒前
bkagyin的应助被科研通管家采纳,获得10
4秒前
4秒前
香蕉觅云的应助被科研通管家采纳,获得10
4秒前
领导范儿的应助被科研通管家采纳,获得10
4秒前
4秒前
晓晓晓完成签到,获得积分10
5秒前
aa的应助被十三月采纳,获得10
5秒前
烟雾镜发布了新的文献求助10
5秒前
6秒前
6秒前
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155816
求助须知:如何正确求助?哪些是违规求助? 9552109
关于积分的说明 21708107
捐赠科研通 7744978
什么是DOI,文献DOI怎么找? 3426225
关于科研通互助平台的介绍 2551237
邀请新用户注册赠送积分活动 2469958